OncLive TV

Paul E. Oberstein, MD, discusses the rationale for the anti-PD-1/IL-15 fusion protein SAR445877 in microsatellite-stable colorectal cancer.

Frank A. Sinicrope, MD, previews 2 colorectal cancer studies to watch at the 2026 ESMO Congress, including adjuvant intensification and AZUR-1.

Ashley Margol, MD, MS, discusses the diagnostic workflow for pediatric low-grade glioma, from biopsy and molecular testing to treatment planning.

Andrea Cercek, MD, discusses the significance of the FDA approval of dostarlimab for dMMR/MSI-H locally advanced rectal cancer.

Julia T. Warren, MD, PhD, discusses the goals and eligibility criteria of the phase 3 4WARD trial of mavorixafor in chronic neutropenia.

Jesús Berdeja, MD, discusses how CELMoDs such as iberdomide and mezigdomide may reshape standard-of-care treatment in multiple myeloma.

Matthew P. Goetz, MD, discusses gedatolisib, treatment sequencing, and co-targeting resistance pathways in HR-positive, HER2-negative advanced breast cancer.

Matthew P. Goetz, MD, discusses oral SERD trial findings, PI3K-pathway therapies, and emerging CDK-targeted treatments in HR-positive advanced breast cancer.

Doris Hansen, MD, discusses the earlier use of CAR T-cell therapy in myeloma and ongoing barriers to access.

Michael G. Fradley, MD, discusses real-world data on atrial fibrillation incidence and its cardiovascular and health care impact in CLL.

Frank A. Sinicrope, MD, discusses the FDA approval of the ATOMIC trial regimen for patients with stage III dMMR colon cancer.

Erika P. Hamilton, MD, discusses how the FDA approval of tucatinib-based first-line maintenance fits into HER2-positive breast cancer care.

Young Kwang Chae, MD, discusses tumor-informed and tissue-agnostic ctDNA MRD assays in postsurgical lung cancer surveillance.

Binod Dhakal, MD, MS, discusses allogeneic and in vivo CAR T-cell therapies under investigation in relapsed/refractory multiple myeloma.

Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, discusses unresolved treatment choices in chronic lymphocytic leukemia.

Meredith Pelster, MD, MSCI, discusses the biomarker-agnostic design of the phase 3 MAPKeeper 301 trial of atebimetinib in metastatic pancreatic cancer.

Alexander N. Shoushtari, MD, discusses the current role, benefits, and limitations of monitoring ctDNA in metastatic uveal melanoma.

Mikkael A. Sekeres, MD, MS, discusses anemia management in lower-risk MDS, from ESAs and luspatercept to the phase 3 development of elritercept.

Moh’d Khushman, MD, discusses the rationale for investigating INCA33890 plus FOLFOX/bevacizumab in the phase 3 setting in patients with MSS/pMMR mCRC.

Rebecca Brown, MD, discusses how the NCCN guideline inclusion of brigatinib is changing clinical practice for NF2-related schwannomatosis.

Philip A. Philip, MD, discusses how tumor treating fields work and their role in locally advanced pancreatic cancer following the Optune Pax FDA approval.

Peter Voorhees, MD, discusses CRS and infection data for etentamig from the phase 3 CERVINO trial in triple-class–exposed relapsed/refractory myeloma.

Peter Voorhees, MD, discusses phase 3 CERVINO data for etentamig vs standard therapies and next steps for the agent in relapsed/refractory myeloma.

Sagar Lonial, MD, FACP, FASCO, discusses MRD-negativity data with iberdomide plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma.

Sagar Lonial, MD, FACP, FASCO, discusses Project Optimus dose selection and MRD as an early end point in the phase 3 EXCALIBER-RRMM trial.

Brad S. Kahl, MD, discusses EA4181 findings, whether cytarabine is needed with BTK inhibition, and the future of chemotherapy-free care in mantle cell lymphoma

Dirk van Esser, MD, discusses safety with KRd in the EMN15/HOVON147 trial and how to select patients with high-risk smoldering myeloma for treatment.

Dirk van Esser, MD, discusses long-term EMN15/HOVON147 data for KRd vs Rd in high-risk smoldering multiple myeloma.

Jessica Encinas Mayoral, PhD, discusses preclinical data on an AI-designed BCMA/FcRL5 trispecific antibody in multiple myeloma.

Jessica Encinas Mayoral, PhD, discusses the design and antigen-independent activity of a BCMA/FcRL5 trispecific antibody in multiple myeloma.